Kathleen Levy
Psychiatry · New York, NYNPI 1679917918
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Axsome Therapeutics, Inc. accounts for 88.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $9,804 and has fallen 73.4% since, to $2,604 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $126.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$13K
- AbbVie$475
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$197
- Corium, LLC$183
- Neurocrine Biosciences, Inc.$183
- Otsuka America Pharmaceutical, Inc.$151
- plus $604 from 10 others
What the payments were for
- Consulting fees$6,90046%
- Speaking & faculty fees$6,20041%
- Food & beverage$2,02013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 15 | $13,327 |
| AbbVie | 32 | $475 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $197 |
| Corium, LLC | 14 | $183 |
| Neurocrine Biosciences, Inc. | 9 | $183 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| Alkermes, Inc. | 7 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $130 |
| Bausch Health US, LLC | 5 | $87 |
| Lundbeck LLC | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Eisai Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $17 |
| Tris Pharma Inc | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$13,100
How this compares
$15,120 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 29 | $54,790 |
| VraylarCariprazine Hcl | 27 | $46,377 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $40,045 |
| TrintellixVortioxetine Hydrobromide | 36 | $30,085 |
| VyvanseLisdexamfetamine Dimesylate | 47 | $18,456 |
| Aripiprazole | 91 | $12,218 |
| Lisdexamfetamine Dimesylate | 51 | $11,914 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 19 | $10,197 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 65 | $8,277 |
| Pramipexole ErPramipexole Di-Hcl | 22 | $7,826 |
| Bupropion XlBupropion Hcl | 284 | $7,274 |
| BelsomraSuvorexant | 11 | $4,702 |
| Vilazodone Hcl | 34 | $4,633 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 32 | $4,429 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 62 | $3,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $151 | $54,79029 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $130 | $48,54183 claims |
| AbbVieVraylar | $475 | $46,37727 claims |
| Alkermes, Inc.Lybalvi | $137 | $40,04524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.